XFOR
Income statement / Annual
Last year (2024), X4 Pharmaceuticals, Inc.'s total revenue was $2.56 M,
and the percentage change from the previous year is not available.
In 2024, X4 Pharmaceuticals, Inc.'s net income was -$37.45 M.
See X4 Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.56 M |
$0.00 |
$0.00 |
$0.00 |
$3.00 M |
$0.00 |
$3.50 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$797.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$672.00 K
|
$103.00 K
|
$195.00 K
|
$300.00 K
|
$400.00 K
|
| Gross Profit |
$1.76 M
|
$0.00
|
$0.00
|
$0.00
|
$3.00 M
|
-$672.00 K
|
$3.40 M
|
-$195.00 K
|
-$300.00 K
|
-$400.00 K
|
| Gross Profit Ratio |
0.69
|
0
|
0
|
0
|
1
|
0
|
0.97
|
0
|
0
|
0
|
| Research and Development Expenses |
$81.64 M
|
$72.02 M
|
$61.06 M
|
$50.65 M
|
$41.93 M
|
$30.16 M
|
$30.98 M
|
$28.13 M
|
$17.83 M
|
$12.71 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$24.70 M
|
$20.94 M
|
$17.64 M
|
$18.41 M
|
$8.01 M
|
$6.52 M
|
$2.12 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$61.52 M
|
$35.51 M
|
$27.02 M
|
$24.70 M
|
$20.94 M
|
$17.64 M
|
$18.41 M
|
$8.01 M
|
$6.52 M
|
$2.12 M
|
| Other Expenses |
-$105.00 M
|
$0.00
|
-$509.00 K
|
$9.76 M
|
$0.00
|
$0.00
|
-$85.00 K
|
-$16.00 K
|
$104.00 K
|
-$77.00 K
|
| Operating Expenses |
$38.16 M
|
$107.52 M
|
$87.57 M
|
$85.11 M
|
$62.87 M
|
$47.80 M
|
$46.21 M
|
$32.27 M
|
$21.96 M
|
$12.67 M
|
| Cost And Expenses |
$38.96 M
|
$107.52 M
|
$87.57 M
|
$85.11 M
|
$62.87 M
|
$47.80 M
|
$46.21 M
|
$32.27 M
|
$21.96 M
|
$12.67 M
|
| Interest Income |
$5.77 M
|
$4.58 M
|
$219.00 K
|
$10.00 K
|
$273.00 K
|
$1.20 M
|
$809.00 K
|
$214.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$8.77 M
|
$5.78 M
|
$3.99 M
|
$3.64 M
|
$2.69 M
|
$2.15 M
|
$1.04 M
|
$2.08 M
|
$2.52 M
|
$472.00 K
|
| Depreciation & Amortization |
$796.00 K
|
$419.00 K
|
$513.00 K
|
$499.00 K
|
$1.23 M
|
$672.00 K
|
$103.00 K
|
$195.00 K
|
$300.00 K
|
$389.00 K
|
| EBITDA |
-$27.58 M |
-$94.89 M |
-$89.33 M |
-$84.54 M |
-$58.07 M |
-$51.70 M |
-$45.89 M |
-$31.60 M |
-$20.16 M |
-$12.35 M |
| EBITDA Ratio |
-10.78
|
0
|
0
|
0
|
-19.36
|
0
|
-13.11
|
0
|
0
|
0
|
| Operating Income Ratio |
-14.24
|
0
|
0
|
0
|
-19.96
|
0
|
-13.11
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$739.00 K
|
$6.43 M
|
-$6.27 M
|
-$3.57 M
|
-$2.11 M
|
-$1.10 M
|
$2.86 M
|
$2.26 M
|
$6.48 M
|
$1.61 M
|
| Income Before Tax |
-$37.14 M
|
-$101.09 M
|
-$93.84 M
|
-$88.68 M
|
-$61.98 M
|
-$52.81 M
|
-$43.02 M
|
-$33.88 M
|
-$22.98 M
|
-$13.22 M
|
| Income Before Tax Ratio |
-14.52
|
0
|
0
|
0
|
-20.66
|
0
|
-12.29
|
0
|
0
|
0
|
| Income Tax Expense |
$310.00 K
|
$78.00 K
|
$28.00 K
|
$17.00 K
|
$148.00 K
|
$0.00
|
$3.90 M
|
$0.00
|
$2.62 M
|
$0.00
|
| Net Income |
-$37.45 M
|
-$101.17 M
|
-$93.87 M
|
-$88.70 M
|
-$62.13 M
|
-$56.60 M
|
-$43.02 M
|
-$33.88 M
|
-$22.98 M
|
-$13.22 M
|
| Net Income Ratio |
-14.65
|
0
|
0
|
0
|
-20.71
|
0
|
-12.29
|
0
|
0
|
0
|
| EPS |
-5.59 |
-17.1 |
-45.6 |
-119.7 |
-92.7 |
-138.9 |
-2373 |
-1637.1 |
-1737.7416 |
-1000.15 |
| EPS Diluted |
-5.59 |
-17.1 |
-45.6 |
-119.7 |
-92.7 |
-138.9 |
-2373 |
-1637.1 |
-1737.7416 |
-1000.15 |
| Weighted Average Shares Out |
$6.70 M
|
$5.93 M
|
$2.06 M
|
$741.70 K
|
$669.23 K
|
$380.07 K
|
$14.03 K
|
$13.43 K
|
$13.24 K
|
$13.24 K
|
| Weighted Average Shares Out Diluted |
$6.70 M
|
$5.93 M
|
$2.12 M
|
$858.29 K
|
$669.23 K
|
$384.33 K
|
$15.30 K
|
$15.27 K
|
$13.24 K
|
$13.24 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
